Published in Radiology on June 14, 2006
How asymptomatic is asymptomatic carotid stenosis? Radiology (2007) 0.78
Can we clinically recognize a vascular depression? The role of personality in an expanded threshold model. Medicine (Baltimore) (2015) 0.76
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
The risk of recurrent venous thromboembolism in men and women. N Engl J Med (2004) 7.41
Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med (2006) 6.51
Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34
D-dimer levels and risk of recurrent venous thromboembolism. JAMA (2003) 3.30
Does carotid stent cell design matter? Stroke (2008) 3.02
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol (2002) 2.88
Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation (2007) 2.80
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29
The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med (2004) 2.27
Gender differences in outcome of conservatively treated patients with asymptomatic high grade carotid stenosis. Stroke (2005) 2.10
Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev (2014) 2.08
Effect of smoking on restenosis during the 1st year after lower-limb endovascular interventions. Radiology (2004) 2.07
Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol (2002) 2.02
Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis (2005) 1.94
Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv (2009) 1.90
Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation (2005) 1.89
Hypotension and bradycardia after elective carotid stenting: frequency and risk factors. J Endovasc Ther (2003) 1.85
D-dimer in ruling out acute aortic dissection: a systematic review and prospective cohort study. Eur Heart J (2007) 1.79
Renal artery PTA and stent implantation: immediate and late clinical and morphological outcome. Wien Klin Wochenschr (2002) 1.69
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging (2004) 1.67
Dental and periodontal status and risk for progression of carotid atherosclerosis: the inflammation and carotid artery risk for atherosclerosis study dental substudy. Stroke (2006) 1.65
Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology (2002) 1.65
Perioperative beta-blockers for preventing surgery-related mortality and morbidity: a systematic review and meta-analysis. Anesth Analg (2007) 1.65
Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J (2004) 1.64
Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart (2009) 1.60
To work in a hospital--a new risk factor for development of venous disease? Wien Klin Wochenschr (2003) 1.57
Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2002) 1.54
A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol (2006) 1.54
One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial. J Endovasc Ther (2009) 1.53
Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur Heart J (2009) 1.53
Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med (2008) 1.52
[Austrian Guidelines for Prophylaxis of Venous Thromboembolism]. Wien Klin Wochenschr (2007) 1.51
Acute-phase response after stent implantation in the carotid artery: association with 6-month in-stent restenosis. Radiology (2003) 1.51
Endovascular revascularization below the knee: 6-month results and predictive value of C-reactive protein level. Radiology (2003) 1.48
Restenosis after femoropopliteal PTA and elective stent implantation: predictive value of monocyte counts. J Endovasc Ther (2003) 1.44
Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke (2003) 1.43
Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther (2005) 1.42
Plaque echolucency is not associated with the risk of stroke in carotid stenting. Stroke (2006) 1.42
Insulin, C-peptide, and restenosis after femoral artery balloon angioplasty in type II diabetic and nondiabetic patients. J Vasc Interv Radiol (2005) 1.42
De novo superficial femoropopliteal artery lesions: peripheral cutting balloon angioplasty and restenosis rates--randomized controlled trial. Radiology (2008) 1.41
Endovascular brachytherapy: restenosis in de novo versus recurrent lesions of femoropopliteal artery--the Vienna experience. Radiology (2005) 1.40
Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor. Thromb Res (2004) 1.39
Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation (2007) 1.37
Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis (2004) 1.35
Inflammation and Carotid Artery--Risk for Atherosclerosis Study (ICARAS). Circulation (2005) 1.32
Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis (2006) 1.26
Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis (2005) 1.23
Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol (2005) 1.19
Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol (2006) 1.18
Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol (2004) 1.13
Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med (2004) 1.09
Incidence and diagnosis of thrombosis in children with short-term central venous lines of the upper venous system. Pediatrics (2008) 1.08
Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther (2005) 1.06
Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol (2003) 1.06
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood (2004) 1.06
Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost (2005) 1.06
Low serum magnesium predicts neurological events in patients with advanced atherosclerosis. Stroke (2003) 1.04
Prognostic impact of fibrinogen in carotid atherosclerosis: nonspecific indicator of inflammation or independent predictor of disease progression? Stroke (2005) 1.03
Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med (2002) 1.02
Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother (2003) 1.02
Weight loss reduces tissue factor in morbidly obese patients. Obes Res (2003) 1.02
First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg (2011) 1.01
Outcome of conservative versus interventional treatment of subclavian artery stenosis. J Endovasc Ther (2002) 1.01